Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 10/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | PIR | O00625 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | STK16 | O75716 | 1/20 | 0.45 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324586 | 0.84 | BRAF (0.49) | AXLNR4A2MAP2K1BRAFJAK2 | |
| SCHEMBL23412702 | 0.84 | F7 (0.56) | AXLNR4A2MAP2K1BRAFJAK2 | |
| SCHEMBL27795046 | 0.84 | BRAF (0.54) | AXLNR4A2MAP2K1BRAFJAK2 | |
| SCHEMBL9938466 | 0.83 | AXL (0.64) | AXLNR4A2MAP2K1CREBBPBRAF | |
| SCHEMBL9938142 | 0.82 | AXL (0.63) | AXLNR4A2MAP2K1CREBBP | |
| SCHEMBL30020999 | 0.82 | AXL (0.63) | AXLNR4A2MAP2K1CREBBP | |
| SCHEMBL30676600 | 0.82 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPBRAF | |
| SCHEMBL1427263 | 0.82 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPBRAF | |
| SCHEMBL28489988 | 0.81 | JAK2 (0.48) | AXLNR4A2MAP2K1BRAFJAK2 | |
| SCHEMBL17321399 | 0.81 | BRAF (0.47) | AXLNR4A2MAP2K1BRAFJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | AXL 4160/4885NR4A2 3995/4885MAP2K1 958/4885 |
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | AXL 2674/4885NR4A2 1975/4885MAP2K1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.